Introduction
============

Epilepsy is a common chronic neurological disorder characterized by epileptic seizures, which vary in their duration. These episodes can range from brief and nearly undetectable seizures to long periods of vigorous shaking ([@b1-ijmm-34-03-0715],[@b2-ijmm-34-03-0715]). In epilepsy, seizures tend to recur, and have no immediate underlying cause, while seizures that occur due to a specific cause are not deemed to represent epilepsy ([@b3-ijmm-34-03-0715]). In the majority of cases, the cause of epilepsy is unknown, although some individuals develop epilepsy as a result of brain injury, stroke, brain cancer or drug and alcohol misuse, among others. Epileptic seizures are the result of excessive and abnormal cortical nerve cell activity in the brain ([@b3-ijmm-34-03-0715]).

Genetics are believed to be involved in the majority of cases of epilepsy, either directly or indirectly. Although some of the genes involved affect ion channels, other molecules such as enzymes, gamma-aminobutyric acid (GABA) and G protein-coupled receptors have been identified as single genes in which defects cause epilepsy; however, epilepsy may occur due to the interaction of multiple genes and environmental factors ([@b4-ijmm-34-03-0715]). The etiology of epilepsy is superficially thought to be multifactorial; however, the genetic factors that may be involved in the pathogenesis of seizures have not yet been elucidated. To study the gene regulatory networks involved in epilepsy, a variety of genome-wide studies have been performed by different groups using various systems and array platforms. The accumulated functional genomic data are freely available in the database of Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) ([@b5-ijmm-34-03-0715],[@b6-ijmm-34-03-0715]), which provides a golden opportunity for compiling a comprehensive list of genetic factors underlying the etiology of epilepsy. According to the approach of differentially expressed gene analysis (DEGA) for studying gene expression profiles, hundreds of significant genes have been identified to be associated with epilepsy. However, few studies have focused on the associated pathways and transcription factors (TFs), as well as on the co-expression patterns at the multiple pathways level.

In the present study, we employed a microarray dataset of genome-wide gene expression profiling from GEO, which is associated with tumor-induced epileptogenesis. The most well-known method of gene set enrichment analysis (GSEA) was used to analyze the genomic data in order to uncover the regulatory mechanisms of human epilepsy caused by brain tumors at the multiple pathways level. GSEA is widely used to analyze gene expression profiles, particularly to identify pre-defined gene sets which exhibit significant differences in expression between samples from the control and treatment groups ([@b7-ijmm-34-03-0715]--[@b9-ijmm-34-03-0715]). The goal of GSEA is to determine other interesting categories (pathways) where the constituent genes show coordinated changes in expression over the experimental conditions, other than in the form of sets of differentially expressed genes (DEGs). One of the advantages of GSEA is the ability to highlight genes weakly connected to the phenotype through pathway analysis, which may be difficult to detect by using classical univariate statistics ([@b7-ijmm-34-03-0715]).

Materials and methods
=====================

Microarray data collection and pre-processing
---------------------------------------------

We searched the GEO database ([www.ncbi.nlm.nih.gov/geo/](www.ncbi.nlm.nih.gov/geo/)) for gene expression profiling studies related to epilepsy. Data were included in our re-analysis if they met the following criteria: i) the data were genome-wide; ii) the comparison was conducted between samples with epilepsy and controls; iii) complete microarray raw or normalized data were available. Finally, we selected the dataset of GSE32534 for our re-analysis, which was contributed by Niesen *et al* ([@b10-ijmm-34-03-0715]). In this dataset, genome-wide gene expression profiling was conducted using the Affymetrix Human Genome U133 Plus 2.0 Array and the RNA was derived from formalin-fixed paraffin-embedded (FFPE) peritumoral cortex tissue slides from 5-paired (seizure vs. non-seizure) low grade brain tumor patients. There were 5 biological replicates for epilepsy \[samples from GSM805925 to GSM805929, marked with epilepsy (EP)-1, EP-2, EP-3, EP-4 and EP-5, respectively\] and 5 for the controls \[samples from GSM805930 to GSM805934, marked with control (CT)-1, CT-2, CT-3, CT-4 and CT-5, respectively\].

For the assessment of the influence of pre-processing on the comparison, data pre-processing was performed using software packages developed in version 2.6.0 of Bioconductor and R version 2.10.1. Each Affymetrix dataset was background adjusted, normalized and log2 probe-set intensities were calculated using the Robust Multichip Averaging (RMA) algorithm in Affy package, as previously described ([@b11-ijmm-34-03-0715]).

GSEA
----

Our GSEA of pathways and genes was performed using the Category package in version 2.6.0 of Bioconductor, as previously described ([@b12-ijmm-34-03-0715]). The goal of GSEA is to determine whether the members of a gene set 'S' are randomly distributed throughout the entire reference gene list 'L' or are primarily found at the top or bottom of the list. One of the advantages of GSEA is the relative robustness to noise and outliers in the data. In our analysis, the gene sets represented by \<10 genes were excluded. The t-statistic mean of the genes was computed in each Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Using a permutation test 1,000 times, the cut-off of the significance level P-values was selected as 0.05 for the significant pathways related to epilepsy. Accordingly, the significant pathways and genes were then identified under the comparison between the samples with epilepsy and no epilepsy. The following classification of identified pathways was based on the KEGG pathway maps br08901 of BRITE Functional Hierarchies in the KEGG database (<http://www.genome.jp/kegg-bin/get_htext?br08901.keg>). The annotation of significant genes in each pathway was performed by using biomaRt package, BioMart v. 0.8 rc3 (version of 0.8 release candidate 3; <http://www.biomart.org/>). Subsequently, clustering of the groups and genes was performed based on the identified gene expression in each significant pathway using the method of hierarchical clustering with Pearson correlation coefficient.

Regulatory elements (REs) and TFs of co-regulated genes
-------------------------------------------------------

We further employed a web server termed DiRE (Distant RE of co-expressed genes, <http://dire.dcode.org/>), based on the enhancer identification (EI) method, to predict common REs for our input genes which have co-function in each identified significantly related pathway ([@b13-ijmm-34-03-0715]). It predicts function-specific REs consisting of clusters of specifically-associated transcription factor binding sites (TFBSs), and it also scores the association of individual TFs with the biological function shared by the group of input genes. We selected a random set of 5,000 genes in the human genome (hg18) as the source of background genes. As a result, there are 2 major parameters of our predicted TFs, including TF occurrence which denotes the percentage of candidate RE containing a conserved binding site for a particular TF; and TF importance which denotes the product of TF occurrence and TF weight. As our candidate associated TFs with input gene sets, we selected the cut-off value of TF importance as \>0.05.

Results and Discussion
======================

Identification of significant pathways associated with epilepsy
---------------------------------------------------------------

In the study of Niesen *et al* ([@b10-ijmm-34-03-0715]), a number of DEGs between the 2 groups (epilepsy and the control) were identified using both the parametric unpaired Student's t-test (345 probe sets representing 296 genes with fold-changes ≥2 plus P≤0.05) and the non-parametric rank product \[377 probe sets representing 344 genes with a false discovery rate (FDR) of ≤0.3\]. Seven DEGs, i.e., *C1QB*, *CALCRL*, *CCR1*, *KAL1*, *SLC1A2*, *SSTR1* and *TYRO3* were validated by qRT-PCR. Moreover, the pathway analysis using DAVID bioinformatics resources revealed that these DEGs were mainly enriched in focal adhesion, extracellular matrix (ECM)-receptor interaction and cell adhesion molecule (CAM) pathways.

Compared to the approach of DEGs, the strategy of GSEA we used in this study is likely to be more powerful than conventional single-gene methods in the study of complex diseases in which many genes make subtle contributions. According to our GSEA on the dataset of 10 samples by the comparison of epilepsy to the controls, in total, there were 72 significant pathways associated with epilepsy, whose P-values were \<0.05, including 4 downregulated and 68 upregulated pathways. The 3 main pathways identified by Niesen *et al* ([@b10-ijmm-34-03-0715]) were also included in our results. Moreover, based on the KEGG pathway maps in the database of KEGG (<http://www.genome.jp/kegg/>), these 72 significant pathways could be mainly mapped into 6 functional classes, including cellular processes, environmental information processing, genetic information processing, human diseases, as well as metabolism and organismal systems. The details of the involved pathways in each class are presented in [Tables I](#tI-ijmm-34-03-0715){ref-type="table"}--[V](#tV-ijmm-34-03-0715){ref-type="table"}. The details of the associated genes in each significant pathway are available upon request (data not shown), including the information on probe set id and gene symbol.

In the functional class of cellular processes, there was 1 significantly downregulated and 8 significantly upregulated pathways associated with epilepsy ([Table I](#tI-ijmm-34-03-0715){ref-type="table"}). These pathways were involved in cell communication, cell growth and death, cell motility, as well as transport and catabolism. Among these, apoptosis was one of the most significant pathways (P\<0.001), which was classified into the functional group of cell growth and death. As is known, high-frequency stimulation (HFS) of the hippocampus may be a promising method in the treatment of epilepsy. It has been indicated that hippocampal HFS can protect hippocampal neurons against kainic acid (KA) neurotoxicity, and that the neuroprotective effects of HFS may be mediated through the inhibition of apoptosis ([@b14-ijmm-34-03-0715]). In total, there were 87 involved genes in the pathway of apoptosis related to epilepsy, which may be clustered into 4 gene set groups based on hierarchical clustering with Pearson correlation coefficient ([Fig. 1](#f1-ijmm-34-03-0715){ref-type="fig"}, groups A--D).

There were 4 and 3 significantly upregulated pathways in the functional class of environmental and genetic information processing, respectively which were associated with epilepsy ([Table II](#tII-ijmm-34-03-0715){ref-type="table"}). The environmental information processing pathways of ECM-receptor interaction (P=0.004) and CAMs (P=0.020) were related to the functions of signaling molecules and interaction, and the ABC transporter pathway (P=0.030) was related to the function of membrane transport, and the Jak-STAT signaling pathway (P=0.046) was related to the function of signal transduction. The genetic information processing pathways of mismatch repair (P=0.031) and DNA replication (P=0.048) were related to the functions of replication and repair, and the RNA polymerase pathway (P=0.008) was transcription related. Among these, the pathway of ECM-receptor interaction was the most significant in this class, which has also been identified as one of the DEG enriched pathways by Niesen *et al* ([@b10-ijmm-34-03-0715]). The ECM is known to regulate important processes in neuronal cell development, activity and growth. The remodeling of the ECM during both development and following injury to the central nervous system has been shown to affect neuronal guidance, synaptic plasticity and their regenerative responses. The functions and potential therapeutic value of several key ECM molecules in epileptogenesis and dementia have been extensively investigated in previous studies ([@b15-ijmm-34-03-0715],[@b16-ijmm-34-03-0715]). The 84 genes involved in the pathway of ECM-receptor interaction may also be clustered into 4 gene set groups ([Fig. 2](#f2-ijmm-34-03-0715){ref-type="fig"}, groups A--D).

Twenty-five significantly associated pathways were classified into the functional class of human diseases, including 5 upregulated and 1 downregulated cancer-related pathways, 4 upregulated cardiovascular disease-related pathways, 1 upregulated endocrine and metabolic disease-related pathway, 6 upregulated immune disease-related pathways and 8 upregulated infectious disease-related pathways ([Table III](#tIII-ijmm-34-03-0715){ref-type="table"}). It has been reported that cardiac changes may accompany epilepsy, which may lead to significant seizure-associated cardiac performance decreases ([@b17-ijmm-34-03-0715]). These data are consistent with the results from our study which identidied 4 significant cardiovascular disease-related pathways associated with epilepsy. Among these, the pathway of hypertrophic cardiomyopathy (HCM) was one of the most significant cardiovascular disease-related pathways (P=0.004). The association between these 2 diseases has been revealed in a clinical case report ([@b18-ijmm-34-03-0715]). In total, there were 83 genes involved in the pathway of HCM associated with epilepsy, which may be clustered into 4 gene set groups ([Fig. 3](#f3-ijmm-34-03-0715){ref-type="fig"}, groups A--D).

In the functional class of metabolism, there were 14 significantly upregulated pathways associated with epilepsy ([Table IV](#tIV-ijmm-34-03-0715){ref-type="table"}). These were involved in 6 different types of metabolism, including amino acid metabolism, carbohydrate metabolism, glycan biosynthesis and metabolism, lipid metabolism, metabolism of co-factors and vitamins, as well as nucleotide metabolism. Among these, the pentose phosphate pathway was one of the most significant pathways (P=0.007), which was classified into the functional group of carbohydrate metabolism. A variety of observations suggested that decreasing glycolysis and increasing the levels of reduced glutathione, generated by the metabolism of glucose through the pentose phosphate pathway, may have an anticonvulsant effect. Fructose-1,6-bisphosphate (F1,6BP) may have anticonvulsant activity in models of acute seizures in adult rats, which shifts the metabolism of glucose from glycolysis to the pentose phosphate pathway ([@b19-ijmm-34-03-0715]). The total of 25 genes involved in the pentose phosphate pathway may be clustered into 3 gene set groups ([Fig. 4](#f4-ijmm-34-03-0715){ref-type="fig"}, groups A--C).

In the last functional class of organismal systems, there were 2 significantly downregulated and 15 significantly upregulated pathways associated with epilepsy ([Table V](#tV-ijmm-34-03-0715){ref-type="table"}). These were involved in development, the nervous system, the endocrine system, as well as the immune system. Among these, the peroxisome proliferator-activated receptor (PPAR) signaling pathway was one of the most associated pathways (P=0.045), which was classified into the functional group of endocrine system. PPAR-γ/mitochondrial uncoupling protein 2 signaling has been reported to protect neurons against seizure-induced neuronal cell death in the hippocampus following experimental status epilepticus ([@b20-ijmm-34-03-0715]). The activation of the mammalian target of rapamycin or PPAR-γ pathways has been considered as one of the pre-clinical models for the anti-epileptogenic activity of a diverse range of potential therapies ([@b21-ijmm-34-03-0715]). Furthermore, there were 68 genes in total which were involved in the PPAR signaling pathway associated with epilepsy, which may be clustered into 4 gene set groups ([Fig. 5](#f5-ijmm-34-03-0715){ref-type="fig"}, groups A--D).

Candidate TF selection related to epilepsy
------------------------------------------

To predict the TFs potentially involved in the regulation of epilepsy, we performed the analysis of TFBSs and the prediction of TFs using the significant genes in each identified pathway. Based n the cut-off value of TF importance, we identified the candidate TFs related to epilepsy with potential target genes which were co-regulated in each of the 72 pathways identified. The details are available upon request.

Among these, the TF of PPAR-γ appeared in several pathways, including fatty acid metabolism, pyrimidine metabolism, the PPAR signaling pathway, lysosome, amoebiasis and melanoma (data available upon request). PPARs belong to the nuclear hormone receptor superfamily. They play critical physiological roles as lipid sensors and regulators of lipid metabolism and are activated by fatty acids ([@b22-ijmm-34-03-0715]). Previous studies have shown that PPAR-γ has anti-inflammatory effects in seizure animal models ([@b20-ijmm-34-03-0715],[@b23-ijmm-34-03-0715]). The anticonvulsant effects of acute pioglitazone on pentylenetetrazol (PTZ)-induced seizures in mice have been demonstrated to be mediated through the PPAR-γ receptor-mediated pathway ([@b24-ijmm-34-03-0715]). One of the PPAR-γ agonists, rosiglitazone, has been proven to protect the central nervous system from oxidative damage in epileptic rats, which may be a potential neuroprotective agent for epilepsy ([@b25-ijmm-34-03-0715]). Our data also support the idea that PPAR-γ may be one of the essential targets for the management of epilepsy due to brain tumors.

Another essential TF of the phosphatidylethanolamine-binding protein (PEBP) was identified in 3 of 4 downregulated pathways, including the GnRH signaling pathway, gap junction and long-term depression pathways. PEBP is alternatively named Raf-1 kinase inhibitor protein, the precursor of the hippocampal cholinergic neurostimulating peptide (HCNP) corresponding to its natural N-terminal fragment, which has been previously described to be released by hippocampal neurons ([@b26-ijmm-34-03-0715]--[@b28-ijmm-34-03-0715]). The crystal structure of human PEBP (hPEBP) suggests that the ligand-binding site may accommodate the phosphate head groups of membrane lipids, therefore allowing the protein to adhere to the inner leaf of bilipid membranes where it would be ideally positioned to relay signals from the membrane to the cytoplasm ([@b29-ijmm-34-03-0715]). With the previous evidence of calpain dysregulation in Alzheimer's disease (AD), PEBP has been confirmed as a novel *in vitro* and *in situ c*alpain substrate using an *in vitro* proteomics approach or serial analysis of gene expression (SAGE) ([@b30-ijmm-34-03-0715],[@b31-ijmm-34-03-0715]). In particular, during brain development, the N-terminal part of mammalian PEBP has been reported to be specifically cleaved and the resulting 11 amino acid peptides may stimulate the growth and activity of acetylcholinergic neurons ([@b32-ijmm-34-03-0715]).
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###### 

Significant pathways associated with epilepsy in the functional class of cellular processes.

  Pathways                                                             Map B                      P-value   No. of genes   No. of TFs
  -------------------------------------------------------------------- -------------------------- --------- -------------- ------------
  04510: Focal adhesion                                                Cell communication         0.009     199            33
  04540[a](#tfn1-ijmm-34-03-0715){ref-type="table-fn"}: Gap junction   Cell communication         0.034     86             27
  04210: Apoptosis                                                     Cell growth and death      \<0.001   87             28
  04115: p53 signaling pathway                                         Cell growth and death      0.018     68             31
  04110: Cell cycle                                                    Cell growth and death      0.035     122            37
  04810: Regulation of actin cytoskeleton                              Cell motility              0.048     211            37
  04146: Peroxisome                                                    Transport and catabolism   \<0.001   78             29
  04142: Lysosome                                                      Transport and catabolism   0.014     111            26
  04145: Phagosome                                                     Transport and catabolism   0.031     141            29

Represents the significantly downregulated pathways associated with epilepsy.

TFs, transcription factors.

###### 

Significant pathways associated with epilepsy in the functional class of environmental and genetic information processing.

  Pathways                                Map B                                 P-value   No. of genes   No. of TFs
  --------------------------------------- ------------------------------------- --------- -------------- ------------
  04512: ECM-receptor interaction         Signaling molecules and interaction   0.004     84             28
  04514: Cell adhesion molecules (CAMs)   Signaling molecules and interaction   0.020     128            41
  02010: ABC transporters                 Membrane transport                    0.030     43             17
  04630: Jak-STAT signaling pathway       Signal transduction                   0.046     153            33
  03020: RNA polymerase                   Transcription                         0.008     27             20
  03430: Mismatch repair                  Replication and repair                0.031     21             20
  03030: DNA replication                  Replication and repair                0.048     35             11

TFs, transcription factors; ECM, extracellular matrix.

###### 

Significant pathways associated with epilepsy in the functional class of human diseases.

  Pathways                                                                   Map B                              P-value   No. of genes   No. of TFs
  -------------------------------------------------------------------------- ---------------------------------- --------- -------------- ------------
  05222: Small cell lung cancer                                              Cancers                            0.008     85             38
  05213[a](#tfn4-ijmm-34-03-0715){ref-type="table-fn"}: Endometrial cancer   Cancers                            0.008     52             30
  05212: Pancreatic cancer                                                   Cancers                            0.011     69             40
  05218: Melanoma                                                            Cancers                            0.012     71             40
  05200: Pathways in cancer                                                  Cancers                            0.022     323            30
  05219: Bladder cancer                                                      Cancers                            0.023     41             16
  05410: Hypertrophic cardiomyopathy (HCM)                                   Cardiovascular diseases            0.004     83             37
  05412: Arrhythmogenic right ventricular cardiomyopathy (ARVC)              Cardiovascular diseases            0.004     74             33
  05416: Viral myocarditis                                                   Cardiovascular diseases            0.034     64             21
  05414: Dilated cardiomyopathy                                              Cardiovascular diseases            0.049     90             37
  04940: Type I diabetes mellitus                                            Endocrine and metabolic diseases   0.013     39             24
  05323: Rheumatoid arthritis                                                Immune diseases                    0.004     83             19
  05322: Systemic lupus erythematosus                                        Immune diseases                    0.013     82             24
  05320: Autoimmune thyroid disease                                          Immune diseases                    0.013     47             20
  05330: Allograft rejection                                                 Immune diseases                    0.013     33             14
  05332: Graft-versus-host disease                                           Immune diseases                    0.013     33             21
  05310: Asthma                                                              Immune diseases                    0.020     26             27
  05100: Bacterial invasion of epithelial cells                              Infectious diseases: Bacterial     0.009     70             36
  05150: Staphylococcus aureus infection                                     Infectious diseases: Bacterial     0.013     48             19
  05146: Amoebiasis                                                          Infectious diseases: Parasitic     \<0.001   106            25
  05145: Toxoplasmosis                                                       Infectious diseases: Parasitic     0.008     120            35
  05140: Leishmaniasis                                                       Infectious diseases: Parasitic     0.008     66             25
  05144: Malaria                                                             Infectious diseases: Parasitic     0.024     48             28
  05142: Chagas disease (American trypanosomiasis)                           Infectious diseases: Parasitic     0.036     101            41
  05160: Hepatitis C                                                         Infectious diseases: Viral         0.018     131            38

Represents the significantly downregulated pathways associated with epilepsy.

TFs, transcription factors.

###### 

Significant pathways associated with epilepsy in the functional class of metabolism.

  Pathways                                                 Map B                                  P-value   No. of genes   No. of TFs
  -------------------------------------------------------- -------------------------------------- --------- -------------- ------------
  00360: Phenylalanine metabolism                          Amino acid metabolism                  0.031     17             26
  00380: Tryptophan metabolism                             Amino acid metabolism                  0.039     42             21
  00030: Pentose phosphate pathway                         Carbohydrate metabolism                0.007     25             39
  00520: Amino sugar and nucleotide sugar metabolism       Carbohydrate metabolism                0.018     46             29
  00010: Glycolysis/gluconeogenesis                        Carbohydrate metabolism                0.024     63             25
  00511: Other glycan degradation                          Glycan biosynthesis and metabolism     0.014     16             22
  00604: Glycosphingolipid biosynthesis - ganglio series   Glycan biosynthesis and metabolism     0.043     15             26
  00071: Fatty acid metabolism                             Lipid metabolism                       0.021     42             22
  00100: Steroid biosynthesis                              Lipid metabolism                       0.032     18             21
  00860: Porphyrin and chlorophyll metabolism              Metabolism of cofactors and vitamins   0.009     30             23
  00770: Pantothenate and CoA biosynthesis                 Metabolism of cofactors and vitamins   0.013     16             20
  00480: Glutathione metabolism                            Metabolism of other amino acids        0.022     47             19
  00230: Purine metabolism                                 Nucleotide metabolism                  \<0.001   155            26
  00240: Pyrimidine metabolism                             Nucleotide metabolism                  0.029     92             43

TFs, transcription factors.

###### 

Significant pathways associated with epilepsy in the functional class of organismal systems.

  Pathways                                                                       Map B              P-value   No. of genes   No. of TFs
  ------------------------------------------------------------------------------ ------------------ --------- -------------- ------------
  04380: Osteoclast differentiation                                              Development        0.004     125            45
  04730[a](#tfn7-ijmm-34-03-0715){ref-type="table-fn"}: Long-term depression     Nervous system     0.004     65             46
  04920: Adipocytokine signaling pathway                                         Endocrine system   0.027     67             31
  04912[a](#tfn7-ijmm-34-03-0715){ref-type="table-fn"}: GnRH signaling pathway   Endocrine system   0.029     94             25
  03320: PPAR signaling pathway                                                  Endocrine system   0.045     68             21
  04650: Natural killer cell mediated cytotoxicity                               Immune system      0.004     125            31
  04670: Leukocyte transendothelial migration                                    Immune system      0.009     113            46
  04610: Complement and coagulation cascades                                     Immune system      0.013     67             25
  04672: Intestinal immune network for IgA production                            Immune system      0.013     44             30
  04640: Hematopoietic cell lineage                                              Immune system      0.014     84             31
  04612: Antigen processing and presentation                                     Immune system      0.017     63             21
  04666: Fc gamma R-mediated phagocytosis                                        Immune system      0.018     90             31
  04620: Toll-like receptor signaling pathway                                    Immune system      0.024     99             30
  04662: B cell receptor signaling pathway                                       Immune system      0.028     74             43
  04621: NOD-like receptor signaling pathway                                     Immune system      0.032     58             20
  04623: Cytosolic DNA-sensing pathway                                           Immune system      0.033     53             17
  04660: T cell receptor signaling pathway                                       Immune system      0.048     108            35

Represents the significantly downregulated pathways associated with epilepsy.

TFs, transcription factors; PPAR, peroxisome proliferator-activated receptor.
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